U.S. Machinery Stock News

NasdaqGS:FRMI
NasdaqGS:FRMISpecialized REITs

Fermi (FRMI) Is Up 10.3% After MUFG’s US$500M Facility For Project Matador Amid Legal Scrutiny

Fermi Inc., operating as Fermi America, recently secured a US$500 million non-recourse “warehouse” loan facility from MUFG Bank to fund Siemens Energy gas turbine purchases and repay an existing loan, supporting its 11-gigawatt Project Matador private energy campus in Texas. This substantial institutional backing arrives while Fermi faces multiple securities class action lawsuits over alleged misstatements about tenant demand and funding for Project Matador, underscoring a tension between...
NYSE:HOG
NYSE:HOGAuto

Harley-Davidson (HOG) Q4 Loss Challenges Bullish Earnings Resilience Narratives

Harley-Davidson (HOG) has wrapped up FY 2025 with a bumpy finish, as Q4 revenue came in at US$496.2 million and the company reported a loss per share of US$2.44, compared to a Q3 stretch that featured US$1.3 billion in revenue and EPS of US$3.13. Over the past few quarters, revenue has moved from US$1.3 billion in Q1 2025, to US$1.3 billion in Q2 and US$1.3 billion in Q3, before easing back to US$496.2 million in Q4. EPS ranged from US$1.07 in Q1 to US$0.89 in Q2 and US$3.13 in Q3, and then...
NYSE:WLK
NYSE:WLKChemicals

Is Westlake (WLK) Fairly Priced After Recent Share Price Rebound?

If you are wondering whether Westlake is offering fair value at its current share price, you are not alone. This article is designed to help you weigh that up in a clear, structured way. The stock last closed at US$99.12, with recent returns of 9.0% over 7 days, 19.1% over 30 days, 33.7% year to date, and a 9.5% decline over 1 year alongside a 15.7% decline over 3 years and a 21.8% gain over 5 years. Recent share price moves sit against a backdrop of ongoing interest in materials and...
NasdaqGS:FISV
NasdaqGS:FISVDiversified Financial

Fiserv (FISV) Margin Expansion Story Tested By 1.4% Revenue Growth

Fiserv (FISV) has wrapped up FY 2025 with fourth quarter revenue of US$5.3b and basic EPS of US$1.51, alongside trailing twelve month revenue of US$21.2b and EPS of US$6.34 that frame the full year picture. Over recent periods the company has seen quarterly revenue range from US$5.1b to US$5.5b, while basic EPS has moved between US$0.98 and US$1.86. This gives you a clear view of how the top line and per share earnings have tracked into the latest print. With a trailing net margin of 16.4%...
NasdaqGS:DOX
NasdaqGS:DOXIT

Amdocs CEO Change And Dividend Lift While Shares Trade Below Targets

Amdocs announced that CEO Shuky Sheffer will retire, and long-time executive Shimie Hortig is set to become Chief Executive Officer. The company also approved an increase in its quarterly dividend, signaling an adjustment to its shareholder return policy. These updates arrive as Amdocs (NasdaqGS: DOX) trades at a share price of $73.13. Amdocs (NasdaqGS: DOX) is going through a leadership handover at the top at the same time its share price has been under pressure. The stock is at $73.13,...
NasdaqGS:APLS
NasdaqGS:APLSBiotechs

Is It Time To Reassess Apellis Pharmaceuticals (APLS) After The Recent Share Price Slide

If you are trying to work out whether Apellis Pharmaceuticals is attractively priced or not, the recent share price and valuation checks give you a lot to think about. The stock last closed at US$22.58, with returns of a 3.2% decline over 7 days, 17.3% decline over 30 days, 12.7% decline year to date, 20.9% decline over 1 year, 56.3% decline over 3 years and 49.5% decline over 5 years. Recent news around Apellis has kept attention on how the market is reassessing risks and opportunities for...
NasdaqGS:GPRE
NasdaqGS:GPREOil and Gas

Why Green Plains (GPRE) Is Up 19.6% After Returning To Profit On Lower Sales - And What's Next

Green Plains Inc. recently reported fourth-quarter 2025 results showing sales of US$428.85 million, down from US$584.02 million a year earlier, but with net income improving to US$11.94 million from a net loss of US$54.94 million. Despite lower ethanol and coproduct volumes across the quarter and full year, the company returned to quarterly profitability, indicating that cost controls and operational efficiencies played a key role in its earnings turnaround. We’ll now examine how this return...
NYSE:LBRT
NYSE:LBRTEnergy Services

A Look At Liberty Energy (LBRT) Valuation After Its US$700 Million Convertible Notes Offering

Liberty Energy (LBRT) has moved to the forefront of investor attention after completing a US$700 million zero coupon senior unsecured convertible notes offering. The company expanded a previously announced US$500 million deal and reshaped its capital structure. See our latest analysis for Liberty Energy. Despite a 23.03% 1 month share price return and a 49.66% 3 month share price return, Liberty Energy has seen some near term volatility. The stock recorded a 3.85% 1 day share price decline...
NasdaqGS:ENTG
NasdaqGS:ENTGSemiconductor

Entegris (ENTG) Margin Decline To 7.4% Tests Bullish Earnings Growth Narratives

Entegris (ENTG) has wrapped up FY 2025 with fourth quarter revenue of US$823.9 million and basic EPS of US$0.33, alongside trailing twelve month revenue of about US$3.2 billion and EPS of US$1.55. Over the past six reported quarters, revenue has moved within a tight band from US$773.2 million to US$849.8 million, while quarterly EPS has ranged from US$0.33 to US$0.68. This gives investors a clear view of how the top line and EPS have tracked together through the cycle. With net income over...
NYSE:BALL
NYSE:BALLPackaging

Ball (BALL) Is Up 9.7% After Guiding Double-Digit 2026 EPS Growth And Maintaining Dividend

In early February 2026, Ball Corporation reported fourth-quarter 2025 results showing sales of US$3,347 million and net income of US$200 million, alongside full-year 2025 sales of US$13.16 billion and diluted earnings per share from continuing operations of US$3.30. Management also projected comparable diluted earnings per share growth of above 10% for 2026 and affirmed a quarterly dividend of US$0.20 per share, underscoring confidence in Ball’s post-divestiture, aluminum-packaging-focused...
NYSE:MNTN
NYSE:MNTNMedia

High Growth Tech Stocks In The US February 2026

As February 2026 begins, the U.S. stock market has seen a robust start with major indices like the Dow Jones Industrial Average and S&P 500 showing significant gains, reflecting positive investor sentiment despite recent economic uncertainties such as government shutdowns and changes in Federal Reserve leadership. In this dynamic environment, identifying high-growth tech stocks requires careful consideration of factors such as innovation potential, adaptability to market shifts, and financial...
NYSE:XPEV
NYSE:XPEVAuto

Discover Autodesk And 2 Other Stocks Estimated To Be Trading Below Fair Value

As the U.S. stock market kicks off February with significant gains, highlighted by the Dow Jones Industrial Average's 515-point surge and the S&P 500 nearing a record high, investors are keenly observing opportunities amid this bullish sentiment. In such an environment, identifying stocks that may be trading below their fair value can present potential investment opportunities, particularly when considering companies like Autodesk and others that might offer strong fundamentals at attractive...
NYSE:PAY
NYSE:PAYDiversified Financial

High Insider Ownership Fuels Growth Stocks In February 2026

As February 2026 begins, U.S. stock markets have shown strong momentum with major indexes like the Dow and S&P 500 ending sharply higher, reflecting investor optimism amid recent economic developments such as trade deals and manufacturing growth. In this buoyant market environment, companies with high insider ownership often attract attention as their leadership's vested interest can signal confidence in long-term growth potential.
NasdaqGS:UDMY
NasdaqGS:UDMYConsumer Services

Cassava Sciences And 2 Other Promising Penny Stocks

As February begins, major U.S. stock indexes have shown a strong start, with the Dow Jones Industrial Average adding 515 points and the S&P 500 nearing record highs. In this context of market optimism, investors may find interest in exploring penny stocks—an investment area that often involves smaller or newer companies. Although the term "penny stocks" might seem outdated, these investments can still offer surprising value and potential for growth when backed by solid financial health.
NasdaqCM:ISBA
NasdaqCM:ISBABanks

Undiscovered Gems in the US Market This February 2026

As February 2026 begins, the U.S. stock market is experiencing a strong start with major indices like the Dow Jones and S&P 500 showing significant gains, reflecting a positive investor sentiment despite recent economic uncertainties such as delayed jobs data due to a government shutdown. In this vibrant yet complex environment, identifying promising small-cap stocks requires careful consideration of factors like market resilience and growth potential amidst evolving economic conditions.
NasdaqGM:CBFV
NasdaqGM:CBFVBanks

Top Dividend Stocks To Consider In February 2026

As February 2026 begins, the U.S. stock market has shown a robust start with major indexes like the Dow Jones Industrial Average and S&P 500 posting significant gains. In this dynamic market environment, dividend stocks can offer investors a blend of income and potential growth, making them an attractive consideration amidst ongoing economic developments.
NasdaqGS:HUMA
NasdaqGS:HUMABiotechs

Why Humacyte (HUMA) Is Up 5.1% After New DoD Funding Backs Symvess Trauma Use

In February 2026, Humacyte, Inc. reported that the U.S. Department of Defense’s Fiscal Year 2026 Appropriations Act includes dedicated funding to evaluate and incorporate biologic vascular repair technologies, directly aligning with its FDA-approved human-derived bioengineered blood vessel Symvess for traumatic extremity vascular injuries in service members. This federal support highlights growing institutional recognition of bioengineered human vessels as an off-the-shelf option when...
NYSE:EVMN
NYSE:EVMNBiotechs

Evommune (EVMN) Valuation Check After Positive Phase 2a EVO301 Results In Atopic Dermatitis

Evommune (EVMN) is back in focus after reporting statistically significant positive top-line results from its Phase 2a EVO301 trial in moderate to severe atopic dermatitis, including clear separation from placebo and a favorable safety readout. See our latest analysis for Evommune. The positive EVO301 data has coincided with a sharp re-rating in the stock, with a 1-day share price return of 70.87% and a year-to-date share price return of 67.71% off a last close of $29.03. This indicates...